"Johnson & Johnson’s CARVYKTI improves survival in multiple myeloma trial" was originally created and published by Clinical ...
After putting on a strong performance in preventing disease progression in the earlier treatment of multiple myeloma, Johnson ...
Johnson & Johnson linked Carvykti to a 45% reduction in risk of death and Darzalex to a 61% improvement in minimal residual ...
Johnson & Johnson reported long-term Phase III CARTITUDE-4 study results showing that a single infusion of Carvykti ...
Johnson & Johnson and Legend Biotech presented new data from the Phase 3 CARTITUDE-4 study, showing Carvykti significantly ...
Investor's Business Daily on MSN1h
Legend Biotech Rises After J&J-Tied Cancer Drug Cuts Risk Of Death By 45%Legend Biotech jumped Monday after the company said its J&J-tied multiple myeloma drug, Cavykti, cut the risk of death.
Legend Biotech's valuation is conservative, suggesting potential for significant appreciation and growth ahead. Click here to ...
Janssen-Cilag International NV, a Johnson & Johnson company, announced three-year follow-up data from the Phase 3 CARTITUDE-4 study ...
RIO DE JANEIRO - Johnson & Johnson (NYSE:JNJ (NYSE:JNJ)) revealed findings from the Phase 3 CARTITUDE-4 study, indicating that CARVYKTI (ciltacabtagene autoleucel) significantly improves overall ...
RIO DE JANEIRO - Johnson & Johnson (NYSE:JNJ) revealed findings from the Phase 3 CARTITUDE-4 study, indicating that CARVYKTI (ciltacabtagene autoleucel) significantly improves overall survival in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback